摘要:
The invention relates to compounds which, acting as a prodrug and/or support, enable an active agent to be taken up by the erythrocytes and/or an active agent to bind to the erythrocytes. The uptake of these compounds by and/or the binding thereof to the erythrocytes is made possible by a group of formula —SO2NR1R2, wherein R1 and R2, independently of each other, mean a hydrogen atom, an acyl group, an alkyl group, a cycloalkyl group, an aryl group, a cyano group or a hydroxy group. The inventive prodrugs enable active agents such as endogenic substances, natural substances and synthetic substances with therapeutically useful properties which have a high “first path” effect, to be administered orally effectively or significantly improve the oral activity thereof.
摘要翻译:本发明涉及作为前药和/或支持物的化合物,使活性剂能够被红细胞和/或活性剂吸收以结合红细胞。 这些化合物通过和/或其与红细胞的结合的吸收通过式-SO 2 NR 1 R 2的基团可以实现,其中R 1和R 2彼此独立地表示氢原子,酰基,烷基, 环烷基,芳基,氰基或羟基。 本发明的前药使得具有高“第一途径”效果的具有治疗有用性质的内源性物质,天然物质和合成物质等活性剂能够有效口服或显着改善其口服活性。
摘要:
The invention relates to new 2-substituted D-homo-estra-1,3,5(10)-trienes of general formula I in which R2 means a C1-C8-alkyl group, a C1-C8-alkyloxy group or a halogen atom, R13 means a hydrogen atom or a methyl group, R17 means a hydrogen atom or a fluorine atom, as well as their pharmaceutically acceptable salts, their manufacture and use as medicaments for prophylaxis and therapy of estrogen-dependent diseases that can be influenced by inhibition of 17β-hydroxy steroid dehydro-genase type 1.
摘要:
A process for the overexpression of dehydrogenases, especially for the overexpression of Δ1-dehydrogenases, in particular for the overexpression of 3-keto steroid-Δ1-dehydrogenases, as well as for the bacteria, plasmids and DNA sequences that can be used for the overexpression, is described.
摘要:
This invention relates to nonsteroidal progesterone receptor modulators of general formula I, a process for their production, the use of progesterone receptor modulators for the production of pharmaceutical agents as well as pharmaceutical compositions that contain these compounds. The compounds according to the invention are suitable for therapy and prophylaxis of gynecological diseases, such as endometriosis, leiomyomas of the uterus, dysfunctional bleeding and dysmenorrhea, as well as for the therapy and prophylaxis of hormone-dependent tumors and for use for female birth control as well as for hormone replacement therapy.
摘要:
The invention relates to the use of perfluoroalkyl-containing metal complexes that have a critical micelle formation concentration 1 nm and a proton relaxivity in plasma (R1)>10 l/mmol·s as contrast media in MR imaging for visualization of intravascular thrombi.
摘要:
The invention relates to new unsaturated 14,15-cyclopropano-androstanes of the general formula (I) to their synthesis and to pharmaceutical compositions, containing these compounds. The compounds of formula (I) have gestagenic and/or androgenic activity.
摘要:
The invention relates to a process for the production of 4-(17α-methyl-substituted 3-oxoestra-4,9-dien-11β-yl)benzaldehyde-(1E or 1Z)-oximes of general formula (I), in which R1 is a hydrogen atom, a C1-6-alkyl radical or a CnF2n+1 radical, whereby n is 1, 2 or 3, R2 is a C1-4-alkyl radical, X is an OH group in E- or Z-position, and Y is an OC1-6-alkyl group, an SC1-6-alkyl group or an OCH2CnF2+1 group, whereby n is 1, 2 or 3, which provides the target compounds of formula (I) with a high yield and good selectivity
摘要:
The novel benzamide derivative represented by formula (1) and the novel anilide derivative represented by formula (13) of this invention has differentiation-inducing effect, and are, therefore, useful a therapeutic or improving agent for malignant tumors, autoimmune diseases, dermatologic diseases and parasitism. In particular, they are highly effective as an anticancer drug, specifically to a hematologic malignancy and a solid carcinoma.